Statement from Jake VanLandingham to the Clarion Ledger:

Prevacus was incorporated in 2012 and has investors and medical/research/athletic associates
from across the world including the State of MS. We are developing the first treatment
solutions for mild traumatic brain injury aka concussion. Our nasal treatment is site-set to
begin human trials. It enters the brain in less than 5-minutes and stimulates DNA to produce
proteins that simultaneously reduce swelling, inflammation and oxidative stress. We are also
currently developing a transdermal treatment that can be taken before activities to reduce
inflammation if you sustain minor or significant head impact (PreSOLMD/PreVPro).
Furthermore, we merged this year with another research company to develop new treatments
for rare brain disorders in children called Leukodystrophies.

In December of 2018 Prevacus leadership was introduced by an investor from MS by phone
to a member of the Mississippi Community Educational Center. We had a few conversations
about Prevacus' current drug development and its role in helping reduce the impact of
concussions on people, especially in our youth. We then decided to have an in-person meeting
in MS with members of both teams to discuss funding the project and what that would mean
for all concerned.

The

meeting

focused on our

drug actions/safety/brain-biodistribution and current

developmental stage. Then we discussed the budget and what was needed at the time to make
the drug available for humans.

Following the meeting communication continued primarily by email and an agreement was
drafted/edited and then signed.

The agreement was between Mississippi Community Education Center (MCEC) a nonprofit and Prevacus, Inc. Based on the budget, agreement and discussions Prevacus was to
work to achieve milestones below and MCEC would have first right of refusal to have clinical
trial Phase 1B in the State of MS as well as exclusive rights to the manufacturing of Prevacus
drugs in the State of MS.

 Milestones for Prevacus
1. complete toxicology and histopathology in animals to develop a safety margin for
prediction in human trials. This was needed to acquire the right dosing.
2. Make previous GLP-certified drug which can NOT be used in humans into GMP-certified
drug that can be used in humans across the world
3. Develop a nano-formulation of the drug that will further reduce side effects and enhance
brain delivery when given nasally.
4. Establish and implement Phase 1A human trials

We have accomplished the above and are site-set to begin human trials in Australia. Following
the completion of that trial we intend to perform Phase 1B at Tradition, MS and have had
several conversations with their leadership. Further we are hopeful when the time comes that
Tradition will have a manufacturing site in place for companies like ours to produce their
drugs, supplements and medical devices. Having a state-of-the-art biotech manufacturing
center in MS will bring many jobs and provide vital treatments to those in need.